Boehringer Ingelheim

Boehringer IngelheimThe Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative "Making more Health" and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 per cent of its net sales.

www.boehringer-ingelheim.com

Boehringer Ingelheim RSS Channel

Display # 
Title Published Date
Boehringer Ingelheim and Harvard scientists establish a research alliance 07 June 2016
Boehringer Ingelheim increases access to the medication for the treatment of HIV/AIDS 30 May 2016
Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing 23 May 2016
New analysis shows only minority of COPD patients may benefit from inhaled corticosteroids 12 April 2016
Boehringer Ingelheim launches RE-COVERY DVT/PE™: global observational study on management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate) 24 March 2016
European Commission confirms CMDh recommendation: Benefit/risk profiles of ambroxol and bromhexine products are favorable 25 January 2016
Boehringer Ingelheim and Arena Pharmaceuticals collaborate to advance research in schizophrenia 19 January 2016
Boehringer Ingelheim 3rd-generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation in lung cancer 22 December 2015
Praxbind® (idarucizumab) approved in European Union for the specific reversal of Pradaxa® (dabigatran etexilate) 26 November 2015
Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years 12 November 2015
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research 11 November 2015
Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD 22 September 2015
International survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes 17 September 2015
Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity 14 August 2015
Patients reporting better quality of communication by their physician show improved self-care 08 June 2015
Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to identify next generation antibodies for cancer treatment 26 May 2015
Boehringer Ingelheim acquires Pharmaxis' phase 1 anti-inflammatory drug candidate 19 May 2015
Boehringer Ingelheim positioned for future growth with product launches 28 April 2015
New international survey of lung cancer oncologists highlights underutilization of personalized treatments 20 April 2015
Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin 20 November 2014

Most Popular Now

AstraZeneca licenses Zurampic to Gr…

AstraZeneca today announced that it has entered into a licensing agreement with Grünenthal GmbH for the exclusive rights to Zurampic (lesinurad) in Europe and Latin Ameri...

Read more

Pfizer presents promising data from…

Pfizer Inc. (NYSE:PFE) today announced encouraging new data from a Phase 1/2 study of lorlatinib, the proposed generic name for PF-06463922, Pfizer's investigational, nex...

Read more

Bayer Science & Education Found…

Applications for the Bayer Science & Education Foundation's international scholarship programs are now being accepted for this year's round. In the academic sector, ambit...

Read more

Merck Accelerator expands its reach…

Merck, a leading science and technology company, has started this week the application period for the next round of its Accelerator programs in Darmstadt, Germany, and Na...

Read more

Call for Abstracts: DIA EuroMeeting…

29 - 31 March 2017, Glasgow, UK. The DIA EuroMeeting 2017 provides a platform for experts from all relevant disciplines within the entire healthcare development and acce...

Read more

Merck announces survey results expl…

Merck, a leading science and technology company, today announced survey results of 250 global biopharmaceutical executives on how their companies will manage new risks as...

Read more

AstraZeneca enters commercialisatio…

AstraZeneca today announced it has entered into a commercialisation agreement with Aspen Global Incorporated (AGI), part of the Aspen Group, for rights to its global anae...

Read more

Promising treatment prospects for i…

In Switzerland alone, more than 5,700 women are diagnosed with breast cancer each year, and almost 1,400 of those affected die of the disease. In many very invasive forms...

Read more

Boehringer Ingelheim and Harvard sc…

Boehringer Ingelheim today announced it has established a research collaboration with the Harvard Stem Cell Institute's - Harvard Fibrosis Network to discover new ways of...

Read more

FDA targets unlawful internet sales…

The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, announced that it took action this week against 4,402 we...

Read more

New class of protein could treat ca…

A protein designed by researchers at Georgia State University can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therap...

Read more

Digital health: A way for pharma co…

Pharmaceutical companies have an opportunity to use their expertise to play a greater role in healthcare reform, while also revamping their business model. We believe t...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]